基于模型评估纳武利尤单抗每4周一次跨瘤种疗效与安全性
本研究采用群体药代动力学建模和暴露-效应分析,在3203例黑色素瘤、非小细胞肺癌、肾细胞癌、头颈部鳞癌、尿路上皮癌或经典型霍奇金淋巴瘤患者中,预测纳武利尤单抗480 mg每4周一次相较3 mg/kg每2周一次的获益-风险特征,结果显示两者安全性及疗效预测相似,且480 mg Q4W提供更便捷灵活的给药选择。
要点
- 480 mg Q4W与3 mg/kg Q2W的稳态暴露相似,关键安全性终点不良事件概率相似。
- 480 mg Q4W预测的总生存期和客观缓解率与3 mg/kg Q2W相当。
- 预测的高瘤内受体占有率支持480 mg Q4W跨瘤种应用。
核心结论
- 预测纳武利尤单抗480 mg每4周一次跨瘤种的获益-风险特征与3 mg/kg每2周一次相似,同时为患者和照护者提供便捷灵活的选择。
研究设计与样本
- 采用群体药代动力学建模和暴露-效应分析,预测3203例黑色素瘤、非小细胞肺癌、肾细胞癌、头颈部鳞癌、尿路上皮癌或经典型霍奇金淋巴瘤患者的药代动力学暴露。
- 定量模型分析暴露-效应,预测480 mg Q4W在所有适应症的安全性及黑色素瘤、NSCLC和RCC的疗效。
- 预测代表不同肿瘤类型的参数下的瘤内受体占有率。
主要发现
- 480 mg Q4W相较3 mg/kg Q2W的时间平均浓度在最初28天更高(26.8%),稳态时相似(5.2%)。
- 480 mg Q4W首剂后峰浓度更高(110.4%),第28天谷浓度更低(-22.1%)。
- 480 mg Q4W达到的峰浓度低于先前确立的安全剂量10 mg/kg Q2W。
- 480 mg Q4W与3 mg/kg Q2W的关键安全性终点不良事件概率相似。
- 480 mg Q4W预测的总生存期和客观缓解率与3 mg/kg Q2W相当。
关键数值与推荐
- 480 mg Q4W与3 mg/kg Q2W时间平均浓度差异:最初28天26.8%,稳态5.2%。
- 480 mg Q4W首剂峰浓度较3 mg/kg Q2W高110.4%,第28天谷浓度低22.1%。
- 480 mg Q4W峰浓度低于10 mg/kg Q2W安全剂量。
临床怎么用
- 基于模型预测,480 mg Q4W可作为与3 mg/kg Q2W获益-风险相似的给药方案,便于临床灵活安排。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab 480 mg every 4 weeks (Q4W) is approved in the European Union, United States, and several other markets across multiple tumor types. Its approval was supported by quantitative efficacy/safety analyses bridging to 3 mg/kg every 2 weeks (Q2W). PATIENTS AND METHODS: The benefit-risk profile of nivolumab 480 mg Q4W relative to 3 mg/kg Q2W was evaluated using population pharmacokinetic modeling and exposure-response (E-R) analyses for safety and efficacy. Pharmacokinetic exposures were predicted for 3203 patients with melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), squamous cell carcinoma of the head and neck, urothelial carcinoma, or classical Hodgkin lymphoma. Quantitative models analyzed E-R to predict 480-mg Q4W safety across all indications and efficacy for melanoma, NSCLC, and RCC. Intratumoral receptor occupancy (RO) was predicted for parameters representing different tumor types. RESULTS: Time-averaged concentrations for 480 mg Q4W versus 3 mg/kg Q2W were higher during the first 28 days (26.8%) and similar at steady state (5.2%). The maximum concentration (Cmax) after the first dose was higher (110.4%), and the trough concentration at day 28 was lower (-22.1%) with 480 mg Q4W versus 3 mg/kg Q2W. The Cmax achieved with 480 mg Q4W was lower than the previously established safe dose of 10 mg/kg Q2W. The probability of adverse events for key safety end points was similar for 480 mg Q4W and 3 mg/kg Q2W. The predicted overall survival and objective response rates with 480 mg Q4W were comparable to 3 mg/kg Q2W. The predicted high intratumoral RO provided additional evidence to support 480 mg Q4W across tumor types. CONCLUSIONS: The benefit-risk profile for nivolumab 480 mg Q4W was predicted to be similar to that of 3 mg/kg Q2W across tumor types while providing a convenient and flexible option for patients and their caregivers.
引用
- Zhao X, Shen J, Ivaturi V, et al. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types. Ann Oncol. 2019. PMID: 31959348. doi:10.1016/j.annonc.2019.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。